Interleukins are a group of cytokines (secreted proteins and signal molecules) that were first seen to be expressed by white blood cells (leukocytes).
The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells.
Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.
History and name
The name "interleukin" was chosen in 1979, to replace the various different names used by different research groups to designate interleukin 1 (lymphocyte activating factor, mitogenic protein, T-cell replacing factor III, B-cell activating factor, B-cell differentiation factor, and "Heidikine") and interleukin 2 (TSF, etc.). This decision was taken during the Second International Lymphokine Workshop in Switzerland (27-31 May 1979 in Ermatingen, 'near' Interlaken).
The term interleukin derives from (inter-) "as a means of communication", and (-leukin) "deriving from the fact that many of these proteins are produced by leukocytes and act on leukocytes". The name is something of a relic, though (the term was coined by Dr Vern Paetkau, University of Victoria) it has since been found that interleukins are produced by a wide variety of body cells.
Some interleukins are classified as lymphokines, lymphocyte-produced cytokines that mediate immune responses.
Common families of interleukins
Interleukin 1 alpha and interleukin 1 beta (IL1 alpha and IL1 beta) are cytokines that participate in the regulation of immune responses, inflammatory reactions, and hematopoiesis. Two types of IL-1 receptor, each with three extracellular immunoglobulin (Ig)-like domains, limited sequence similarity (28%) and different pharmacological characteristics have been cloned from mouse and human cell lines: these have been termed type I and type II receptors. The receptors both exist in transmembrane (TM) and soluble forms: the soluble IL-1 receptor is thought to be post-translationally derived from cleavage of the extracellular portion of the membrane receptors.
Both IL-1 receptors (CD121a/IL1R1, CD121b/IL1R2) appear to be well conserved in evolution, and map to the same chromosomal location. The receptors can both bind all three forms of IL-1 (IL-1 alpha, IL-1 beta and IL-1 receptor antagonist).
The crystal structures of IL1A and IL1B have been solved, showing them to share the same 12-stranded beta-sheet structure as both the heparin binding growth factors and the Kunitz-type soybean trypsin inhibitors. The beta-sheets are arranged in 4 similar lobes around a central axis, 8 strands forming an anti-parallel beta-barrel. Several regions, especially the loop between strands 4 and 5, have been implicated in receptor binding.
Molecular cloning of the Interleukin 1 Beta converting enzyme is generated by the proteolytic cleavage of an inactive precursor molecule. A complementary DNA encoding protease that carries out this cleavage has been cloned. Recombinant expression enables cells to process precursor Interleukin 1 Beta to the mature form of the enzyme.
Interleukin 1 also plays a role in the Central Nervous System. Research indicates that mice with a genetic deletion of the type I IL-1 receptor display markedly impaired hippocampal-dependent memory functioning and Long-term potentiation, although memories that do not depend on the integrity of the hippocampus seem to be spared. However, when mice with this genetic deletion have wild-type neural precursor cells injected into their hippocampus and these cells are allowed to mature into astrocytes containing the interleukin-1 receptors, the mice exhibit normal hippocampal-dependent memory function, and partial restoration of long-term potentiation.
T lymphocytes regulate the growth and differentiation of T cells and certain B cells through the release of secreted protein factors. These factors, which include interleukin 2 (IL2), are secreted by lectin- or antigen-stimulated T cells, and have various physiological effects. IL2 is a lymphokine that induces the proliferation of responsive T cells. In addition, it acts on some B cells, via receptor-specific binding, as a growth factor and antibody production stimulant. The protein is secreted as a single glycosylated polypeptide, and cleavage of a signal sequence is required for its activity. Solution NMR suggests that the structure of IL2 comprises a bundle of 4 helices (termed A-D), flanked by 2 shorter helices and several poorly defined loops. Residues in helix A, and in the loop region between helices A and B, are important for receptor binding. Secondary structure analysis has suggested similarity to IL4 and granulocyte-macrophage colony stimulating factor (GMCSF).
Interleukin 3 (IL3) is a cytokine that regulates hematopoiesis by controlling the production, differentiation and function of granulocytes and macrophages. The protein, which exists in vivo as a monomer, is produced in activated T cells and mast cells, and is activated by the cleavage of an N-terminal signal sequence.
IL3 is produced by T lymphocytes and T-cell lymphomas only after stimulation with antigens, mitogens, or chemical activators such as phorbol esters. However, IL3 is constitutively expressed in the myelomonocytic leukaemia cell line WEHI-3B. It is thought that the genetic change of the cell line to constitutive production of IL3 is the key event in development of this leukaemia.
Interleukin 4 (IL4) is produced by CD4+ T cells specialized in providing help to B cells to proliferate and to undergo class switch recombination and somatic hypermutation. Th2 cells, through production of IL-4, have an important function in B-cell responses that involve class switch recombination to the IgG1 and IgE isotypes.
Interleukin 5 (IL5), also known as eosinophil differentiation factor (EDF), is a lineage-specific cytokine for eosinophilpoiesis. It regulates eosinophil growth and activation, and thus plays an important role in diseases associated with increased levels of eosinophils, including asthma. IL5 has a similar overall fold to other cytokines (e.g., IL2, IL4 and GCSF), but while these exist as monomeric structures, IL5 is a homodimer. The fold contains an anti-parallel 4-alpha-helix bundle with a left handed twist, connected by a 2-stranded anti-parallel beta-sheet. The monomers are held together by 2 interchain disulphide bonds.
Interleukin 6 (IL6), also referred to as B-cell stimulatory factor-2 (BSF-2) and interferon beta-2, is a cytokine involved in a wide variety of biological functions. It plays an essential role in the final differentiation of B cells into immunoglobulin-secreting cells, as well as inducing myeloma/plasmacytoma growth, nerve cell differentiation, and, in hepatocytes, acute-phase reactants.
A number of other cytokines may be grouped with IL6 on the basis of sequence similarity. These include granulocyte colony-stimulating factor (GCSF) and myelomonocytic growth factor (MGF). GCSF acts in hematopoiesis by affecting the production, differentiation, and function of 2 related white cell groups in the blood. MGF also acts in hematopoiesis, stimulating proliferation and colony formation of normal and transformed avian cells of the myeloid lineage.
Cytokines of the IL6/GCSF/MGF family are glycoproteins of about 170 to 180 amino acid residues that contain four conserved cysteine residues involved in two disulphide bonds. They have a compact, globular fold (similar to other interleukins), stabilised by the two disulphide bonds. One half of the structure is dominated by a 4-alpha-helix bundle with a left-handed twist; the helices are anti-parallel, with two overhand connections, which fall into a double-stranded anti-parallel beta-sheet. The fourth alpha-helix is important to the biological activity of the molecule.
Interleukins 7 and 9
Interleukin 7 (IL-7) is a cytokine that serves as a growth factor for early lymphoid cells of both B- and T-cell lineages. Interleukin 9 (IL-9) is a cytokine that supports IL-2 independent and IL-4 independent growth of helper T cells. Interleukin 7 and 9 seem to be evolutionary related.
Interleukin 10 (IL-10) is a protein that inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF, and GM-CSF produced by activated macrophages and by helper T cells. In structure, IL-10 is a protein of about 160 amino acids that contains four conserved cysteines involved in disulphide bonds. IL-10 is highly similar to the Human herpesvirus 4 (Epstein-Barr virus) BCRF1 protein, which inhibits the synthesis of gamma-interferon and to Equid herpesvirus 2 (Equine herpesvirus 2) protein E7. It is also similar, but to a lesser degree, with human protein mda-7. a protein that has antiproliferative properties in human melanoma cells. Mda-7 contains only two of the four cysteines of IL-10.
Interleukin 11 (IL-11) is a secreted protein that stimulates megakaryocytopoiesis, resulting in increased production of platelets, as well as activating osteoclasts, inhibiting epithelial cell proliferation and apoptosis, and inhibiting macrophage mediator production. These functions may be particularly important in mediating the hematopoietic, osseous and mucosal protective effects of interleukin 11.
Interleukin 12 (IL-12) is a disulphide-bonded heterodimer consisting of a 35kDa alpha subunit and a 40kDa beta subunit. It is involved in the stimulation and maintenance of Th1 cellular immune responses, including the normal host defence against various intracellular pathogens, such as Leishmania, Toxoplasma, Measles virus, and Human immunodeficiency virus 1 (HIV). IL-12 also has an important role in enhancing the cytotoxic function of NK cells and role in pathological Th1 responses, such as in inflammatory bowel disease and multiple sclerosis. Suppression of IL-12 activity in such diseases may have therapeutic benefit. On the other hand, administration of recombinant IL-12 may have therapeutic benefit in conditions associated with pathological Th2 responses.
Interleukin 13 (IL-13) is a pleiotropic cytokine that may be important in the regulation of the inflammatory and immune responses. It inhibits inflammatory cytokine production and synergises with IL-2 in regulating interferon-gamma synthesis. The sequences of IL-4 and IL-13 are distantly related.
Interleukin 15 (IL-15) is a cytokine that possesses a variety of biological functions, including stimulation and maintenance of cellular immune responses. IL-15 stimulates the proliferation of T lymphocytes, which requires interaction of IL-15 with components of IL-2R, including IL-2R beta and probably IL-2R gamma, but not IL-2R alpha.
Interleukin 17 (IL-17) is a potent proinflammatory cytokine produced by activated memory T cells. The IL-17 family is thought to represent a distinct signalling system that appears to have been highly conserved across vertebrate evolution.
List of human interleukins
||macrophages, B cells, monocytes, dendritic cells 
||T helper cells
||maturation & proliferation 
|macrophages, endothelium, other
||inflammation, small amounts induce acute phase reaction, large amounts induce fever
||CD25/IL2RA, CD122/IL2RB, CD132/IL2RG
||activated T cells and B cells, NK cells, macrophages, oligodendrocytes
||stimulates growth and differentiation of T cell response. Can be used in immunotherapy to treat cancer or suppressed for transplant patients. Has also been used in clinical trials (ESPIRIT. Stalwart) to raise CD4 counts in HIV positive patients.
||activated T helper cells, mast cells, NK cells, endothelium, eosinophils
||hematopoietic stem cells
||differentiation and proliferation of myeloid progenitor cells  to e.g. erythrocytes, granulocytes
||growth and histamine release
||Th2 cells, just activated naive CD4+ cell, memory CD4+ cells, mast cells, macrophages
||activated B cells
||proliferation and differentiation, IgG1 and IgE synthesis. Important role in allergic response (IgE)
||increase expression of vascular cell adhesion molecule (VCAM-1) promoting adhesion of lymphocytes.
||Th2 cells, mast cells, eosinophils
||differentiation, IgA production
||macrophages, Th2 cells, B cells, astrocytes, endothelium
||activated B cells
||differentiation into plasma cells
|hematopoietic stem cells
|T cells, others
||induces acute phase reaction, hematopoiesis, differentiation, inflammation
||Bone marrow stromal cells and thymus stromal cells
||pre/pro-B cell, pre/pro-T cell, NK cells
||differentiation and proliferation of lymphoid progenitor cells, involved in B, T, and NK cell survival, development, and homeostasis, ↑proinflammatory cytokines
|IL-8 or CXCL8
||macrophages, lymphocytes, epithelial cells, endothelial cells
||neutrophils, basophils, lymphocytes
||Th2 cells, specifically by CD4+ helper cells
||T cells, B cells
||Potentiates IgM, IgG, IgE, stimulates mast cells
||monocytes, Th2 cells, CD8+ T cells, mast cells, macrophages, B cell subset
||inhibits Th1 cytokine production (IFN-γ, TNF-β, IL-2)
||bone marrow stroma
||bone marrow stroma
||acute phase protein production, osteoclast formation
||dendritic cells, B cells, T cells, macrophages
||activated  T cells,
||differentiation into Cytotoxic T cells with IL-2, ↑ IFN-γ, TNF-α, ↓ IL-10
||↑ IFN-γ, TNF-α
||activated Th2 cells, mast cells, NK cells
||TH2-cells, B cells, macrophages
||Stimulates growth and differentiation of B cells (IgE), inhibits TH1-cells and the production of macrophage inflammatory cytokines (e.g. IL-1, IL-6), ↓ IL-8, IL-10, IL-12
||T cells and certain malignant B cells
||activated B cells
||controls the growth and proliferation of B cells, inhibits Ig secretion
||mononuclear phagocytes (and some other cells), especially macrophages following infection by virus(es)
||T cells, activated B cells
||Induces production of Natural killer cells
||lymphocytes, epithelial cells, eosinophils, CD8+ T cells
||CD4+ T cells (Th-cells)
||T helper 17 cells (Th17)
||epithelium, endothelium, other
||osteoclastogenesis, angiogenesis, ↑ inflammatory cytokines
||Th1 cells, NK cells
||Induces production of IFNγ, ↑ NK cell activity
||Activated keratinocytes and monocytes
||regulates proliferation and differentiation of keratinocytes
||activated T helper cells, NKT cells
||All lymphocytes, dendritic cells
||costimulates activation and proliferation of CD8+ T cells, augment NK cytotoxicity, augments CD40-driven B cell proliferation, differentiation and isotype switching, promotes differentiation of Th17 cells
||T helper 17 cells (Th17)
||Production of defensins from epithelial cells. Activates STAT1 and STAT3 and increases production of acute phase proteins such as serum amyloid A, Alpha 1-antichymotrypsin and haptoglobin in hepatoma cell lines
||macrophages, dendritic cells
||Maintenance of IL-17 producing cells, increases angiogenesis but reduces CD8 T-cell infiltration
||melanocytes, keratinocytes, monocytes, T cells
||Plays important roles in tumor suppression, wound healing and psoriasis by influencing cell survival, inflammatory cytokine expression.
||T Cells, mast cells, eosinophils, macrophages, mucosal epithelial cells
||Induces the production IL-4, IL-5 and IL-13, which stimulate eosinophil expansion
||T cells, monocytes
||Enhances secretion of IL-10 and IL-8 and cell surface expression of CD54 on epithelial cells
||macrophages, dendritic cells
||Regulates the activity of B lymphocyte and T lymphocytes
||Plays a role in immune defense against viruses
||Plays a role in host defenses against microbes
||Forms one chain of IL-27
||May play a role in inflammation of the skin
||Induces monocytes and macrophages to secrete TNF-α, IL-8 and CXCL2
||Induces helper T cells to produce type 2 cytokine
||regulatory T cells
||Suppression of T helper cell activation
||Regulates DC and T cell responses
INNs for pharmaceutical analogues and derivatives
- ^ Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V (Oct 2010). "Evolutionary divergence and functions of the human interleukin (IL) gene family". Human Genomics. 5 (1): 30–55. PMC 3390169 . PMID 21106488. doi:10.1186/1479-7364-5-1-30.
- ^ a b c Ben Menachem-Zidon O, Avital A, Ben-Menahem Y, Goshen I, Kreisel T, Shmueli EM, Segal M, Ben Hur T, Yirmiya R (Jul 2011). "Astrocytes support hippocampal-dependent memory and long-term potentiation via interleukin-1 signaling". Brain, Behavior, and Immunity. 25 (5): 1008–16. PMID 21093580. doi:10.1016/j.bbi.2010.11.007.
- ^ di Giovine FS, Duff GW (Jan 1990). "Interleukin 1: the first interleukin". Immunology Today. 11 (1): 13–20. PMID 2405873. doi:10.1016/0167-5699(90)90005-t.
- ^ Schindler R, Dinarello CA (1990). "Interleukin 1". In Habenicht A. Growth Factors, Differentiation Factors, and Cytokines. Berlin, Heidelberg: Springer. ISBN 978-3-642-74856-1. doi:10.1007/978-3-642-74856-1_7.
- ^ "Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors". Journal of Immunology. 123 (6): 2928–9. Dec 1979. PMID 91646.
- ^ PDB: 3LTQ; Barthelmes K, Reynolds AM, Peisach E, Jonker HR, DeNunzio NJ, Allen KN, Imperiali B, Schwalbe H (Feb 2011). "Engineering encodable lanthanide-binding tags into loop regions of proteins". Journal of the American Chemical Society. 133 (4): 808–19. PMC 3043167 . PMID 21182275. doi:10.1021/ja104983t.
- ^ Sims JE, March CJ, Cosman D, Widmer MB, MacDonald HR, McMahan CJ, Grubin CE, Wignall JM, Jackson JL, Call SM (Jul 1988). "cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily". Science. 241 (4865): 585–9. PMID 2969618. doi:10.1126/science.2969618.
- ^ Liu C, Hart RP, Liu XJ, Clevenger W, Maki RA, De Souza EB (Aug 1996). "Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA". The Journal of Biological Chemistry. 271 (34): 20965–72. PMID 8702856. doi:10.1074/jbc.271.34.20965.
- ^ McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, Grubin CE, Wignall JM, Jenkins NA, Brannan CI (Oct 1991). "A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types". The EMBO Journal. 10 (10): 2821–32. PMC 452992 . PMID 1833184.
- ^ Priestle JP, Schär HP, Grütter MG (Dec 1989). "Crystallographic refinement of interleukin 1 beta at 2.0 A resolution". Proceedings of the National Academy of Sciences of the United States of America. 86 (24): 9667–71. PMC 298562 . PMID 2602367. doi:10.1073/pnas.86.24.9667.
- ^ Murzin AG, Lesk AM, Chothia C (Jan 1992). "beta-Trefoil fold. Patterns of structure and sequence in the Kunitz inhibitors interleukins-1 beta and 1 alpha and fibroblast growth factors". Journal of Molecular Biology. 223 (2): 531–43. PMID 1738162. doi:10.1016/0022-2836(92)90668-A.
- ^ Avital A, Goshen I, Kamsler A, Segal M, Iverfeldt K, Richter-Levin G, Yirmiya R (2003). "Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity". Hippocampus. 13 (7): 826–34. PMID 14620878. doi:10.1002/hipo.10135.
- ^ Yokota T, Arai N, Lee F, Rennick D, Mosmann T, Arai K (Jan 1985). "Use of a cDNA expression vector for isolation of mouse interleukin 2 cDNA clones: expression of T-cell growth-factor activity after transfection of monkey cells". Proceedings of the National Academy of Sciences of the United States of America. 82 (1): 68–72. PMC 396972 . PMID 3918306. doi:10.1073/pnas.82.1.68.
- ^ a b Cerretti DP, McKereghan K, Larsen A, Cantrell MA, Anderson D, Gillis S, Cosman D, Baker PE (May 1986). "Cloning, sequence, and expression of bovine interleukin 2". Proceedings of the National Academy of Sciences of the United States of America. 83 (10): 3223–7. PMC 323485 . PMID 3517854. doi:10.1073/pnas.83.10.3223.
- ^ a b Mott HR, Driscoll PC, Boyd J, Cooke RM, Weir MP, Campbell ID (Aug 1992). "Secondary structure of human interleukin 2 from 3D heteronuclear NMR experiments". Biochemistry. 31 (33): 7741–4. PMID 1510960. doi:10.1021/bi00148a040.
- ^ a b Dorssers L, Burger H, Bot F, Delwel R, Geurts van Kessel AH, Löwenberg B, Wagemaker G (1987). "Characterization of a human multilineage-colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in mouse interleukin-3". Gene. 55 (1): 115–24. PMID 3497843. doi:10.1016/0378-1119(87)90254-X.
- ^ a b c d e Ymer S, Tucker WQ, Sanderson CJ, Hapel AJ, Campbell HD, Young IG (1985). "Constitutive synthesis of interleukin-3 by leukaemia cell line WEHI-3B is due to retroviral insertion near the gene". Nature. 317 (6034): 255–8. PMID 2413359. doi:10.1038/317255a0.
- ^ a b Campbell HD, Tucker WQ, Hort Y, Martinson ME, Mayo G, Clutterbuck EJ, Sanderson CJ, Young IG (Oct 1987). "Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5)". Proceedings of the National Academy of Sciences of the United States of America. 84 (19): 6629–33. PMC 299136 . PMID 3498940. doi:10.1073/pnas.84.19.6629.
- ^ a b c d Milburn MV, Hassell AM, Lambert MH, Jordan SR, Proudfoot AE, Graber P, Wells TN (May 1993). "A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5". Nature. 363 (6425): 172–6. PMID 8483502. doi:10.1038/363172a0.
- ^ a b Proudfoot AE, Davies JG, Turcatti G, Wingfield PT (May 1991). "Human interleukin-5 expressed in Escherichia coli: assignment of the disulfide bridges of the purified unglycosylated protein". FEBS Letters. 283 (1): 61–4. PMID 2037074. doi:10.1016/0014-5793(91)80553-F.
- ^ a b c Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A (1986). "Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin". Nature. 324 (6092): 73–6. PMID 3491322. doi:10.1038/324073a0.
- ^ a b c Lütticken C, Krüttgen A, Möller C, Heinrich PC, Rose-John S (May 1991). "Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6". FEBS Letters. 282 (2): 265–7. PMID 2037043. doi:10.1016/0014-5793(91)80491-K.
- ^ a b c Clogston CL, Boone TC, Crandall BC, Mendiaz EA, Lu HS (Jul 1989). "Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor". Archives of Biochemistry and Biophysics. 272 (1): 144–51. PMID 2472117. doi:10.1016/0003-9861(89)90205-1.
- ^ Walter MR, Cook WJ, Zhao BG, Cameron RP, Ealick SE, Walter RL, Reichert P, Nagabhushan TL, Trotta PP, Bugg CE (Oct 1992). "Crystal structure of recombinant human interleukin-4". The Journal of Biological Chemistry. 267 (28): 20371–6. PMID 1400355.
- ^ Henney CS (May 1989). "Interleukin 7: effects on early events in lymphopoiesis". Immunology Today. 10 (5): 170–3. PMID 2663018. doi:10.1016/0167-5699(89)90175-8.
- ^ Renauld JC, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J (Jun 1990). "Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene". Journal of Immunology. 144 (11): 4235–41. PMID 1971295.
- ^ Boulay JL, Paul WE (Sep 1993). "Hematopoietin sub-family classification based on size, gene organization and sequence homology". Current Biology. 3 (9): 573–81. PMID 15335670. doi:10.1016/0960-9822(93)90002-6.
- ^ Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, Wlodawer A (Jun 1995). "Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma". Structure. 3 (6): 591–601. PMID 8590020. doi:10.1016/S0969-2126(01)00193-9.
- ^ Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB (Dec 1995). "Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression". Oncogene. 11 (12): 2477–86. PMID 8545104.
- ^ Leng SX, Elias JA (1997). "Interleukin-11". The International Journal of Biochemistry & Cell Biology. 29 (8-9): 1059–62. PMID 9416001. doi:10.1016/S1357-2725(97)00017-4.
- ^ a b c Abbas AK, Lichtman AH, Pillai S (2012). Cellular and molecular immunology (7th ed.). Philadelphia: Elsevier/Saunders. ISBN 1437715281.
- ^ Zhang C, Zhang J, Niu J, Zhou Z, Zhang J, Tian Z (Aug 2008). "Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D". Human Immunology. 69 (8): 490–500. PMID 18619507. doi:10.1016/j.humimm.2008.06.004.
- ^ Park AY, Scott P (Jun 2001). "Il-12: keeping cell-mediated immunity alive". Scandinavian Journal of Immunology. 53 (6): 529–32. PMID 11422900. doi:10.1046/j.1365-3083.2001.00917.x.
- ^ Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH (1998). "The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses". Annual Review of Immunology. 16: 495–521. PMID 9597139. doi:10.1146/annurev.immunol.16.1.495.
- ^ Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B (Mar 1993). "Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses". Nature. 362 (6417): 248–50. PMID 8096327. doi:10.1038/362248a0.
- ^ Seyfizadeh, N., Seyfizadeh, N., Babaloo, Z. (2014). "Interleukin-13 as an Important Mediator: A Review on its Roles in Some Human Diseases", Iranian Journal of Allergy, Asthma and Immunology, In Press.
- ^ Arena A, Merendino RA, Bonina L, Iannello D, Stassi G, Mastroeni P (Apr 2000). "Role of IL-15 on monocytic resistance to human herpesvirus 6 infection". The New Microbiologica. 23 (2): 105–12. PMID 10872679.
- ^ a b Aggarwal S, Gurney AL (Jan 2002). "IL-17: prototype member of an emerging cytokine family". Journal of Leukocyte Biology. 71 (1): 1–8. PMID 11781375.
- ^ a b c d Unless else specified in boxes, then ref is: Lippincott's Illustrated Reviews: Immunology. Paperback: 384 pages. Publisher: Lippincott Williams & Wilkins; (July 1, 2007). Language: English. ISBN 0-7817-9543-5. ISBN 978-0-7817-9543-2. Page 68
- ^ Noosheen Alaverdi; David Sehy (2007-05-01). "Cytokines - Master Regulators of the Immune System" (PDF). eBioscience. Retrieved 2008-02-28.
- ^ a b c d e f g h i j k l m n o p Cytokine tutorial, The University of Arizona
- ^ Kotowicz K, Callard RE, Friedrich K, Matthews DJ, Klein N (Dec 1996). "Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor". Int Immunol. 8 (12): 1915–25. PMID 8982776. doi:10.1093/intimm/8.12.1915.
This article incorporates text from the public domain Pfam and InterPro IPR000779